CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: Drug Pricing; FDA; NIH; biodefense/pandemic; CDC; science/math education; U.S. Preventive Services Task Force; eLabeling; Orphan Drug Tax Credit Support legislation to reform Congressional Budget Office scoring of health care legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Health Issues HCR
Support FDA user fee programs and review process consistency and predictability. Support FDA modernization practices Support legislation proposing coverage for multicancer screening Oppose domestic manufacturing/procurement mandates for pharmaceutical products, APIs, & medical devices Support public education campaign on pandemic preparedness Oppose drug importation proposals Support diversity in clinical trial policy Support medical device change control plans legislation Oppose legislation that expands Medicare Drug Pricing Negotiation Program Support bipartisan Pandemics and All Hazards Preparedness Reauthorization Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development (PASTEUR Act) Support legislation providing for e-labeling of medical devices
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Medicare/Medicaid MMM
Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem Oppose drug importation proposals Support capping Medicare beneficiary out of pocket costs Support expanded access to telehealth Support value-based purchasing provision, but oppose line extensions and co-pay assistance provisions of CMS Medicaid VBP proposed rule Implement Medicare Drug Price Negotiation program in least harmful way - MFP at ceiling for innovative products, broad orphan drug exclusion, welcome patient and stakeholder input
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Taxation/Internal Revenue Code TAX
Support R&D and NOL tax incentives, Orphan Drug Tax Credits, repeal R&D tax amortization
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Medical/Disease Research/Clinical Labs MED
Support NIH research funding Support promulgation of TCET rule Support breakthrough device coverage bill Support bipartisan PAHPA reauthorization
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Copyright/Patent/Trademark CPT
Address concerns with provisions of patent litigation reform, including inter partes review Oppose "march-in" rights and "compulsory licensing" proposals Support transferable exclusivity extensions to incentivize novel antibiotic R&D
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Trade (domestic/foreign) TRD
Oppose proposals to reduce data exclusivity Oppose proposals to restrict data uses Oppose WTO TRIPS waiver for COVID diagnostics and therapeutics
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CUNNINGHAM | — |
| BRENTON J. FISK New | — |
| ANTHONY THEISSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.